Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival
Open Access
- 15 May 1996
- Vol. 77 (10) , 1978-1985
- https://doi.org/10.1002/(sici)1097-0142(19960515)77:10<1978::aid-cncr3>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- Chemotherapy of advanced gastric carcinoma: To be completely rewritten?Annals of Oncology, 1994
- Adenocarcinoma of the stomach: are we making progress?The Lancet, 1993
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993
- Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970British Journal of Surgery, 1992
- Gastric cancer: Chemotherapy of advanced diseaseHematological Oncology, 1992
- Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.Journal of Clinical Oncology, 1991
- Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell linesBritish Journal of Cancer, 1991
- Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.Journal of Clinical Oncology, 1986
- A phase II study of cisplatin in advanced gastric cancerEuropean Journal of Cancer and Clinical Oncology, 1983